These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25700648)

  • 61. Unmet needs in the treatment of autoimmunity: from aspirin to stem cells.
    Chang C
    Autoimmun Rev; 2014; 13(4-5):331-46. PubMed ID: 24462645
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Conventional basis therapy of rheumatoid arthritis. Effects within and outside cells].
    Keyßer G
    Z Rheumatol; 2012 Aug; 71(6):468-72. PubMed ID: 22802023
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Emerging Therapies for Rheumatoid Arthritis.
    Kalden JR
    Rheumatol Ther; 2016 Jun; 3(1):31-42. PubMed ID: 27747522
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Is fat that bad in rheumatoid arthritis?
    Clavel G; Sigaux J; Semerano L
    Joint Bone Spine; 2019 Mar; 86(2):129-130. PubMed ID: 30025960
    [No Abstract]   [Full Text] [Related]  

  • 65. Regarding the Ambiguity of the Medical Terms "Biologics" and "Biological Agents".
    Sugawara H
    Intern Med; 2016; 55(16):2327. PubMed ID: 27523023
    [No Abstract]   [Full Text] [Related]  

  • 66. Updated Greek Rheumatology Society Guidelines for the Management of Rheumatoid Arthritis.
    Vassilopoulos D; Aslanidis S; Boumpas D; Kitas G; Nikas SN; Patrikos D; Sfikakis PP; Sidiropoulos P
    Mediterr J Rheumatol; 2020 Jun; 31(Suppl 1):163-171. PubMed ID: 32676575
    [No Abstract]   [Full Text] [Related]  

  • 67. Biological Agents and Therapeutic Plasma Exchange: Can They Coexist in the Future?
    Kronbichler A
    Ther Apher Dial; 2017 Dec; 21(6):553-555. PubMed ID: 29205892
    [No Abstract]   [Full Text] [Related]  

  • 68. [Sex-specific aspects in rheumatology].
    Albrecht K; Ohrndorf S; Strangfeld A
    Z Rheumatol; 2024 Jun; ():. PubMed ID: 38869669
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Success for a new generation of disease-modifying antirheumatic drugs : The Janus kinase inhibitor baricitinib in rheumatoid arthritis].
    Keyßer G
    Z Rheumatol; 2017 Jun; 76(5):461-462. PubMed ID: 28447156
    [No Abstract]   [Full Text] [Related]  

  • 70. A Summary of 2018 and What Lies Ahead for Rheumatology and Therapy in 2019.
    Fleischmann R
    Rheumatol Ther; 2019 Mar; 6(1):1-3. PubMed ID: 30612320
    [No Abstract]   [Full Text] [Related]  

  • 71. Cost-effectiveness of biologics compared with disease-modifying antirheumatic drugs in rheumatoid arthritis.
    Patel AM; Lupash D; Chew D; Levesque MC; Moreland LW
    Curr Rheumatol Rep; 2011 Oct; 13(5):381-2. PubMed ID: 21755323
    [No Abstract]   [Full Text] [Related]  

  • 72. Correction to: Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials.
    Welzel T; Winskill C; Zhang N; Woerner A; Pfister M
    Pediatr Rheumatol Online J; 2021 Aug; 19(1):124. PubMed ID: 34399784
    [No Abstract]   [Full Text] [Related]  

  • 73. On Modern Treatment by Drugs.
    Crosby TB
    Br Med J; 1871 Feb; 1(529):164-5. PubMed ID: 20746120
    [No Abstract]   [Full Text] [Related]  

  • 74. Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins.
    Benucci M; Li Gobbi F; Meacci F; Manfredi M; Infantino M; Severino M; Testi S; Sarzi-Puttini P; Ricci C; Atzeni F
    Biologics; 2015; 9():7-12. PubMed ID: 25733803
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.
    Amiot A; Peyrin-Biroulet L
    Therap Adv Gastroenterol; 2015 Mar; 8(2):66-82. PubMed ID: 25729432
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Rheumatoid arthritis: Perioperative management of biologics and DMARDs.
    Goodman SM
    Semin Arthritis Rheum; 2015 Jun; 44(6):627-32. PubMed ID: 25747348
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial.
    Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Walker D; Kelly C; Birrell F; Chakravarty K; Maddison P; Heslin M; Patel A; Kingsley GH
    BMJ; 2015 Mar; 350():h1046. PubMed ID: 25769495
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Rheumatoid arthritis: an evolutionary force in biologics.
    Brown PM; Isaacs JD
    Curr Pharm Des; 2015; 21(17):2170-8. PubMed ID: 25760301
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Michaelis-Menten elimination kinetics of etanercept, rheumatoid arthritis biologics, after intravenous and subcutaneous administration in rats.
    Lee BY; Kwon KI; Kim MS; Baek IH
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):433-9. PubMed ID: 25725773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.